iRucaparib-AP6 is a highly efficient and specific PROTAC PARP1 degrader. iRucaparib-AP6, a non-trapping PARP1 degrader, blocks both the catalytic activity and scaffolding effects of PARP1 In Vitro iRucaparib-AP6 (0-10 μM; 24 hours) decreases PARP-1 level in a dose dependent manner, exhibits a half-maximal degrading concentration (DC 50 ) of 82 nM (D max = 92%). iRucaparib-AP6 (0-20 μM; 24 hours) induces degradation of PARP1 at low concentrations. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: Primary rat neonatal cardiomyocyte cells Concentration: 0.001 μM; 0.01 μM; 0.1 μM; 1 μM; 10 μM Incubation Time: 24 hours Result: Decreased PARP-1 level in primary rat neonatal cardiomyocyte cells. Western Blot AnalysisCell Line: Primary rat neonatal cardiomyocyte cells Concentration: 0.05 μM; 0.1 μM; 0.2 μM; 0.5 μM; 1 μM; 2 μM; 5 μM;10 μM; 20 μM Incubation Time: 24 hours Result: Induced robust PARP1 degradation at concentrations as low as 50 nM. Form:Solid IC50& Target:PARP1 82 nM (DC 50 )